911 Improved lifelines needed for all lines: real-world treatment patterns and attrition rates in US patients with non-driver mutation metastatic non-small cell lung cancer

Abstract

BackgroundImmunotherapy with PD-(L)1-based strategies has rapidly transformed the treatment landscape for non-driver mutation metastatic non-small cell lung cancer (NSCLC). However, it is unclear how recent immunotherapy approvals have translated into...